menu
    • menu
    [{"orgOrder":0,"company":"Premier Research Group","sponsor":"Seaport Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Premier Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Premier Research Group \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Premier Research Group \/ Premier Research Group"},{"orgOrder":0,"company":"Premier Research Group","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Premier Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Premier Research Group \/ Premier Research Group","highestDevelopmentStatusID":"11","companyTruncated":"Premier Research Group \/ Premier Research Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Premier Research Group

    Menu

    Premier Research Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Premier Research Group

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Premier Research Group

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amphetamine Sulfate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Recipient : Aytu BioPharma, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

                            Details : Amphetamine Sulfate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : Amphetamine Sulfate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Recipient : Aytu BioPharma, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Premier Research Group

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Premier Research Group

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glyph Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Seaport Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants W...

                            Details : Glyph Allopregnanolone is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : Glyph Allopregnanolone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Seaport Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth